Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lucy Ginn"'
Publikováno v:
PLoS ONE, Vol 17, Iss 5, p e0268300 (2022)
Chemoresistance poses a great barrier to breast cancer treatment and is thought to correlate with increased matrix stiffness. We developed two-dimensional (2D) polyacrylamide (PAA) and three-dimensional (3D) alginate in vitro models of tissue stiffne
Externí odkaz:
https://doaj.org/article/eda66da8f4c74a25a7443d5701b3abd4
Publikováno v:
Non-Coding RNA, Vol 6, Iss 3, p 25 (2020)
Lung cancer is associated with a high mortality, with around 1.8 million deaths worldwide in 2018. Non-small-cell lung cancer (NSCLC) accounts for around 85% of cases and, despite improvement in the management of NSCLC, most patients are diagnosed at
Externí odkaz:
https://doaj.org/article/100001f706354c58a00dd0b77960b8fe
Publikováno v:
Cancer Gene Therapy. 28:175-187
Non-small-cell lung cancer (NSCLC) is the most prevalent form of lung cancer and has a poor five-year survival rate of 15%. Chemotherapy and targeted therapies have significantly improved patients' prognosis. Nevertheless, after a successful initial
Publikováno v:
PLoS ONE
Chemoresistance poses a great barrier to breast cancer treatment and is thought to correlate with increased matrix stiffness. We developed two-dimensional (2D) polyacrylamide (PAA) and three-dimensional (3D) alginate in vitro models of tissue stiffne
Publikováno v:
Reviews in Medical Virology
La Montagna, M, Shi, L & Ginn, L 2020, ' Diverse roles of long non-coding RNAs in viral diseases ', Reviews in Medical Virology . https://doi.org/10.1002/rmv.2198
La Montagna, M, Shi, L & Ginn, L 2020, ' Diverse roles of long non-coding RNAs in viral diseases ', Reviews in Medical Virology . https://doi.org/10.1002/rmv.2198
Summary Viral infection leads to large alterations in the host transcriptome and stimulates an antiviral host immune response involving numerous proteins and signalling pathways. Long non‐coding RNAs (lncRNAs) have emerged as important regulators d
Publikováno v:
Cancer gene therapy. 28(3-4)
Non-small-cell lung cancer (NSCLC) is the most prevalent form of lung cancer and has a poor five-year survival rate of 15%. Chemotherapy and targeted therapies have significantly improved patients' prognosis. Nevertheless, after a successful initial
Publikováno v:
Non-Coding RNA, Vol 6, Iss 25, p 25 (2020)
La Montagna, M, Ginn, L, Shi, L & Garofalo, M 2020, ' LncRNAs in non-small-cell lung cancer ', Non-Coding RNA, vol. 6, no. 3, 25 . https://doi.org/10.3390/NCRNA6030025
Non-Coding RNA
La Montagna, M, Ginn, L, Shi, L & Garofalo, M 2020, ' LncRNAs in non-small-cell lung cancer ', Non-Coding RNA, vol. 6, no. 3, 25 . https://doi.org/10.3390/NCRNA6030025
Non-Coding RNA
Lung cancer is associated with a high mortality, with around 1.8 million deaths worldwide in 2018. Non-small-cell lung cancer (NSCLC) accounts for around 85% of cases and, despite improvement in the management of NSCLC, most patients are diagnosed at